Clinical trial NCT00456313: No Resistance After Long Term Treatment SERETIDE
Official title: Rationale for Therapy With Low Dose Steroids Combined With Long-acting beta2-agonists in Patients With Allergic Asthma: Redirecting Innate Immune Responses by Long-term Treatment With High Doses of Inhaled Steroids
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Asthma
Keywords: asthma
fluticasone propionate
salmeterol/fluticasone propionate
combination product
innate immune response
neutrophil priming
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2007-04-04
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This multi centre, double blind, comparator controlled, parallel group study is to determine whether asthma treatment with high doses of fluticasone propionate (FP) redirects a Th2/ eosinophil response towards a more treatment resistant neutrophil/ monocyte response and whether this occurs to a lesser extent in asthmatic subjects treated with the combination product of salmeterol and fluticasone propionate (SFC). The primary endpoint is the mean change in priming of blood neutrophils assessed by marker A17. After a run-in period of 4 weeks subjects will enter a 24 weeks high dose treatment (FP 500 mcg bd) or a 12 week medium-dose treatment with FP 250 mcg bd followed by a 12 week treatment with SFC 50/ 250 mcg. At the visits lung function measurements, ACT, eNO measurements and a blood sample will be performed. A total of 50 randomised subjects are planned to be recruited in this study


Eligibility criteria: Inclusion:

* Positive skin prick test
* History of asthma (GINA)
* Regular treatment with FP with/without LABA at least 4 weeks before visit 1
* History of recurrent episodes of wheezing, breathlessness, chest tightness and/ or coughing in the previous year.
* Able to use a DISKUS™ inhaler
* Able perform reproducible lung function tests at Visit 1

Inclusion criteria treatment period:

* FEV1 % predicted \> 70%
* ACT score \< 25 after run-in period

Exclusion criteria run-in period:

* Hospitalised for asthma within 4 weeks prior to Visit 1
* Acute upper respiratory tract infection or a lower respiratory tract infection within 4 weeks prior to Visit 1
* Oral, parental or depot corticosteroids within 4 weeks prior to Visit 1
* Hepatic impairment or other significant disease

Exclusion criteria treatment period:

* Non-compliance (\< 70%)

Primary outcomes:
measure: Mean change in neutrophil priming in blood as assessed by marker A17
timeFrame: on going
Secondary outcomes:
measure: Activation in markers such as A27, CD11b, L-selection, CD16, CD32, VLA-4 and CD66b in whole blood- Cytokine/chemokine determination by multiplex assay in cell free serum- Asthma control measured - Lung function: FEV1, FVC and PEF- eNO
timeFrame: on going
Other outcomes:
Locations:
city: Utrecht
country: Netherlands
facility: GSK Investigational Site
city: Utrecht
country: Netherlands
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: